ACETAZOLAMIDE (acetazolamide) by NERx Biosciences is carbonic anhydrase inhibitors [moa]. Approved for heart failure, glaucoma. First approved in 2023.
Drug data last refreshed 20h ago
Carbonic Anhydrase Inhibitors
Carbonic Anhydrase Inhibitor
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men
HighCycle Study: Effect of Acetazolamide on Sleep Disordered Breathing in Women Compared to Men
HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men
Acetazolamide and Exercise Performance at Altitude
Worked on ACETAZOLAMIDE at NERx Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.